EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces the appointment of Lewis J. Stuart as Chief Commercial Officer. Mr. Stuart joined NovaBay on December 1 and brings more than 30 years of biopharmaceutical industry experience. At NovaBay, he will be responsible for leading all commercial activities, including driving sales and revenue growth of Avenova in new and existing markets, and expanding the Company’s global commercial channel.
“Lewis is a results-driven executive with extensive experience in successfully launching and growing major medical products, making him an ideal fit for this position,” said Mark Sieczkarek, NovaBay’s President and CEO. “He joins us with a track record of launching first-in-class products, a focus on maximizing productivity and strategic insights. We look for Lewis to make impactful contributions to our commercial organization as we focus on accelerating sales growth of Avenova, and welcome him to our Company.”
“Avenova offers multiple important benefits to a large and relatively untapped segment of the ophthalmology market,” commented Mr. Stuart. “I am delighted to join the NovaBay team and look forward to leading the commercial operations and driving Avenova’s ongoing success.”
Prior to NovaBay, Mr. Stuart was Vice President, U.S. Oncology for Genomic Health, where he led the marketing, sales, and medical affairs teams for their oncology franchise. He was also a member of the Board of Directors for Linkage Biosciences, Inc. recently acquired by Thermo Fisher, Inc.
Previously, he served as President and General Manager of Genetic Technologies, a women’s health/oncology company, where he established a U.S.-based molecular diagnostics division. He has also held leadership positions as Senior Vice President, Commercial Operations at CV Therapeutics, a Gilead Sciences acquisition, and Vice President, Sales & Community Marketing at Agouron Pharmaceuticals, before its acquisition by Pfizer, Inc.
Mr. Stuart holds a BA in Communications & Marketing Management from Virginia Polytechnic and State University.
About Avenova®
Avenova is NovaBay
Pharmaceuticals’ main commercial focus. Data from a multicenter clinical
study show that Avenova reduced bacterial load, the underlying cause of
blepharitis, on ocular skin surface by more than 90%. Laboratory tests
show that hypochlorous acid has potent antimicrobial activity in
solution yet is non-toxic to mammalian cells and also neutralizes
bacterial toxins. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It
is accessible from more than 90% of retail pharmacies in the U.S.
through agreements with McKesson Corporation, Cardinal Health and
AmerisourceBergen.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay
Pharmaceuticals, Inc. is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX® family of products and the AGANOCIDE®
compounds. The Neutrox family of products includes AVENOVA®
for the eye care market, NEUTROPHASE® for wound care market,
and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target applications
in the dermatology and urology markets.
Forward-Looking Statements
This release contains
forward-looking statements that are based upon management's current
expectations, assumptions, estimates, projections and beliefs. These
statements include, but are not limited to, statements regarding any
potential benefit or deleterious effect due to the transition in
management, inclusive of any possible effect that would have generally
on the Company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors that
may cause actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such differences
include, but are not limited to, risks and uncertainties relating to
difficulties or delays in manufacturing, distributing, and selling the
Company's products, unexpected adverse side effects or inadequate
therapeutic efficacy of our product, the uncertainty of patent
protection for the Company's intellectual property, and any potential
regulatory problems. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release, are
detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the
Securities and Exchange Commission, especially under the heading "Risk
Factors." The forward-looking statements in this release speak only as
of this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required by
law.
Socialize and Stay informed on NovaBay’s
progress:
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit NovaBay’s Website
